Using Ferumoxytol for MRI in Atherosclerosis Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and effectiveness of Ferumoxytol as a contrast agent for magnetic resonance angiography (MRA) in patients with atherosclerosis. Participants will undergo safety assessments through vital signs and laboratory tests before and after Ferumoxytol administration. Following the injection, patients will have two MRI scans at specified intervals to assess the diagnostic utility of Ferumoxytol. The study will prospectively enroll eligible patients and document their pre-administration lab results as part of routine clinical assessments.

Why it matters

Who can join: the full rules

Inclusion criteria: Patients aged 18 years and older with atherosclerosis.

Exclusion criteria:

Individuals with a history of allergy or hypersensitivity to iron or dextran. Patients currently receiving oral or intravenous iron therapy. Patients with hemosiderosis or hemochromatosis. Patients with a history of allergic reactions to intravenous iron products or any iron overload-related conditions.

Individuals who are unable to undergo magnetic resonance imaging (MRI) due to psychological reasons (such as claustrophobia) or physical reasons (such as the presence of non-compatible metallic objects in the body).

Patients with end-stage diseases or life expectancy less than 1 year. Pregnant women. Any other individuals deemed unsuitable for inclusion by the investigator.

Where it's running

• Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Jing Liang
• Email: liangjingxyz@163.com
• Phone: 18262638917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Clazakizumab for adults with high hsCRP at risk for a heart event

  This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.

  Recruiting at 32 sites Phase 2 Eli Lilly and Company · Huntsville, Alabama and 45 other locations · NCT07783802

• Cilostazol and Aspirin to Prevent Heart and Brain Events in Type 2 Diabetes

  In people with type 2 diabetes and higher cardiovascular risk, researchers are testing whether taking cilostazol plus aspirin can help reduce major heart and brain events.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07719894

• Dapagliflozin to slow coronary plaque progression in type 2 diabetes

  This trial tests whether adding dapagliflozin to standard care can slow or reverse coronary plaque buildup in adults with type 2 diabetes and stable coronary disease.

  Recruiting at 2 sites Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07614230

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.